CLEVELAND, Feb. 3, 2015 /PRNewswire/ -- ViewRay, a privately held medical device company, announced today that University Hospital Agostino Gemelli of the Catholic University of the Sacred Heart in Rome, Italy, has placed an order for its MRIdian (me-rid-i-an) system, the world’s first and only clinically available MRI-guided radiation therapy system for the treatment of cancer.
The MRIdian system is designed to improve the accuracy of cancer treatments through a patented combination of simultaneous Magnetic Resonance Imaging (MRI) and radiation therapy delivery. With continuous soft-tissue imaging, clinicians can more clearly see the cancer target, monitor where the actual radiation dose is being delivered, and adapt to changes in the patient’s anatomy all in real time, providing a more precise and personalized cancer treatment option.
“We are excited about the opportunity to bring the benefits of MRI-guided radiation therapy to patients in Europe,” said Chris A. Raanes, ViewRay president and CEO. “University Hospital Agostino Gemelli is a prestigious institution, known for its commitment to international education, research and clinical collaboration, and they will be valuable members of ViewRay’s growing team of elite healthcare customers.”
University Hospital Agostino Gemelli of the Catholic University of the Sacred Heart cares for the highest number of cancer patients in Italy and serves as the official hospital to the papacy, having cared for Pope John Paul II throughout his long pontificate.
“Our mission is to deliver world-class medical services and conduct research using the most advanced medical techniques available,” said Vincenzo Valentini, M.D., professor of radiation oncology at the University Hospital Agostino Gemelli and past president of ESTRO, the European Society of Radiotherapy and Oncology. “Continual MR image guidance during radiotherapy delivery on the MRIdian system is poised to establish a new level of care for cancer patients.”
MRIdian systems have been ordered by 13 leading cancer centers worldwide, including the Sylvester Comprehensive Cancer Center at University of Miami, the UCLA Jonsson Comprehensive Cancer Center, the University of Wisconsin Carbone Cancer Center, and the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
About ViewRay
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy. For more information, visit http://www.viewray.com.
ViewRay and MRIdian are trademarks of ViewRay Incorporated.
ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viewray-receives-first-european-order-for-its-mridian-system-300029802.html
SOURCE ViewRay
Help employers find you! Check out all the jobs and post your resume.
